November is Epilepsy Awareness Month, and we want to shine a light on the cannabinoid therapies that are showing promise with epilepsy diagnoses today.
Epilepsy affects over 65 million people across the globe. Cannabinoid therapy is being widely researched and documented for its potential to bring seizure control and symptomatic relief to those affected; helping children and adults to live an enhanced quality of life.
Studies Show Promising Results
Epilepsy is the fourth most common neurological condition in the world. In December of 2017, a promising study put on by The Journal of Epilepsy Research found that cannabidiol (CBD) had a positive effect in reducing seizures. They stated the following, “In these studies, CBD was found to be superior to placebo in reducing the frequency of convulsive (tonic-clonic, tonic, clonic, and atonic) seizures in patients with Dravet syndrome, and the frequency of drop seizures in patients with Lennox-Gastaut syndrome (LGS). For the first time, there is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes.”
The research suggests that CBD interacts with the receptors in our brains in different ways to possibly prevent seizures from happening.
A Holistic Alternative
In 2017, a study was performed in which participants who found common medication ineffective tried CBD. The results showed that the median frequency of seizures decreased from 12.4 to 5.9 in the treatment group, while the placebo group showed a far less significant change from 14.9 to 14.1. CBD therapy was particularly effective with patients that were having seizures with convulsions.
Promise for Research
Approved by the FDA in 2018, EPIDIOLEX is a prescription CBD isolate, originally prescribed to pediatrics who suffer from Dravet Syndrome or LGS. To date, it has gone through several clinical trials, making it possible to understand more about CBD as a potential therapy to those affected by Epilepsy. These clinical studies, along with observational research, are furthering our knowledge and understanding of how CBD may help us and our loved ones achieve that quality of life.
If you would like to participate in our observational research registry with John Hopkins University, please go to realmofcaring.org/orr to access your baseline survey. This is completely valuable to researchers, providers, other clients, and caregivers to help make informed decisions about medical cannabis use.
If you have any questions about this topic, a Realm of Caring Care Specialist is here to help. Call us at 719-347-5400 option 1, email us at firstname.lastname@example.org, or visit our website and sign up for a free client account at www.realmofcaring.org.
The Realm of Caring Foundation specifically invokes the first amendment rights of freedom of speech and of the press without prejudice. These statements have not been evaluated by the food and drug administration. the products discussed are not intended to diagnose, cure, prevent or treat any disease. Realm of Caring always recommends when and wherever possible that licensed local healthcare professionals be consulted.
The Realm of Caring Foundation is an independent nonprofit with its own governing board. We do not produce or sell cannabinoid products, nor do we receive funds from the sale of other company’s products.